The University of Queensland

PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics era

Ryder, Simon J., Love, Amanda J., Duncan, Emma L. and Pattison, David A. (2021). PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics era. Clinical Endocrinology, 95 (1), 13-28. doi: 10.1111/cen.14375

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A. ... TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 397 (10276), 797-804. doi: 10.1016/S0140-6736(21)00237-3

Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation

Arnfield, Evyn G., Thomas, Paul A., Roberts, Matthew J., Pelecanos, Anita M., Ramsay, Stuart C., Lin, Charles Y., Latter, Melissa J., Garcia, Peter L. and Pattison, David A. (2021). Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. European Journal of Nuclear Medicine and Molecular Imaging, 48 (13), 4495-4507. doi: 10.1007/s00259-021-05456-3

Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol

Iravani, Amir, Solomon, Benjamin, Pattison, David A., Jackson, Price, Ravi Kumar, Aravind, Kong, Grace, Hofman, Michael S., Akhurst, Tim and Hicks, Rodney J. (2019). Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol. Thyroid, 29 (11), 1634-1645. doi: 10.1089/thy.2019.0143

Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT

Pattison, David A., MacFarlane, Lisa L., Callahan, Jason, Kane, Emma L., Akhurst, Timothy and Hicks, Rodney J. (2019). Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. EJNMMI Research, 9 (1) 15, 15. doi: 10.1186/s13550-019-0480-2

18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation

Pattison, David A., Bozin, Michael, Gorelik, Alexandra, Hofman, Michael S., Hicks, Rodney J. and Skandarajah, Anita (2017). 18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. Journal of Nuclear Medicine, 59 (5), 749-755. doi: 10.2967/jnumed.117.198085

Molecular imaging in the investigation of hypoglycaemic syndromes and their management

Pattison, David A. and Hicks, Rodney J. (2017). Molecular imaging in the investigation of hypoglycaemic syndromes and their management. Endocrine-Related Cancer, 24 (6), R203-R221. doi: 10.1530/erc-17-0005

Management of distant metastasis in differentiated thyroid cancer

Pattison, David A., Miller, Julie A., Khavar, Bhadrakant and Tie, Jeanne (2018). Management of distant metastasis in differentiated thyroid cancer. Evidence-Based Endocrine Surgery. (pp. 121-140) Singapore: Springer Singapore. doi: 10.1007/978-981-10-1124-5_11

First-in-Human²¹²Pb-PSMA–Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer

Griffiths, Matthew R., Pattison, David A., Latter, Melissa, Kuan, Kevin, Taylor, Stephen, Tieu, William, Kryza, Thomas, Meyrick, Danielle, Lee, Boon Quan, Hansen, Aaron, Rose, Stephen E. and Puttick, Simon G. (2024). First-in-Human212Pb-PSMA–Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 65 (4), jnumed.123.267189-664. doi: 10.2967/jnumed.123.267189

The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort

Tariq, Arsalan, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Pelecanos, Anita, Gan, Chun Loo, Goh, Jeffrey C., Wong, David, McBean, Rhiannon, Marsh, Phillip, Goodman, Steven, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John W., Thomas, Paul, Pattison, David A. and Roberts, Matthew J. (2024). The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort. European Urology Focus. doi: 10.1016/j.euf.2023.12.004

Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer

Buteau, James P., Moon, Daniel, Fahey, Michael T., Roberts, Matthew J., Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, De Abreu Lourenco, Richard, Dhillon, Haryana M., Kasivisvanathan, Veeru, Francis, Roslyn J., Stricker, Phillip, Agrawal, Shihka, O'Brien, Jonathan, McVey, Aoife, Sharma, Gaurav, Levy, Sidney, Ayati, Narjess, Nguyen, Andrew, Lee, Su-Faye, Pattison, David A., Sivaratnam, Dinesh, Frydenberg, Mark, Du, Yang, Titus, Jehan, Lee, Sze-Ting, Ischia, Joseph, Jack, Greg ... Emmett, Louise (2023). Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. European Urology Oncology. doi: 10.1016/j.euo.2023.11.008

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R, Williams, Scott G ... Yip, Sonia (2023). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. The Lancet Oncology, 25 (1), 99-107. doi: 10.1016/s1470-2045(23)00529-6

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

Pathmanathan, Shivanshan, Tariq, Arsalan, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Marsh, Phillip, Goodman, Steven, Dhiantravan, Nattakorn, Esler, Rachel, Dunglison, Nigel, Navaratnam, Anojan, Yaxley, John, Thomas, Paul, Pattison, David A., Goh, Jeffrey C., Gan, Chun Loo and Roberts, Matthew J. (2023). Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management. European Journal of Nuclear Medicine and Molecular Imaging, 51 (1), 295-303. doi: 10.1007/s00259-023-06380-4

Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI

Arnfield, Evyn G., Tam, Laura, Pattison, David A., Younger, John, Chikatamarla, Venkata Avinash, Wyld, David, Burge, Matthew, McCormack, Louise, Ladwa, Rahul and Ramsay, Stuart (2023). Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI. Journal of Nuclear Cardiology, 30 (6), 1-16. doi: 10.1007/s12350-023-03345-w

Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06

Barry, Nathaniel, Francis, Roslyn J., Ebert, Martin A., Koh, Eng-Siew, Rowshanfarzad, Pejman, Hassan, Ghulam Mubashar, Kendrick, Jake, Gan, Hui K., Lee, Sze T., Lau, Eddie, Moffat, Bradford A., Fitt, Greg, Moore, Alisha, Thomas, Paul, Pattison, David A., Akhurst, Tim, Alipour, Ramin, Thomas, Elizabeth L., Hsiao, Edward, Schembri, Geoffrey P., Lin, Peter, Ly, Tam, Yap, June, Kirkwood, Ian, Vallat, Wilson, Khan, Shahroz, Krishna, Dayanethee, Ngai, Stanley, Yu, Chris ... Scott, Andrew M. (2023). Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06. European Journal of Nuclear Medicine and Molecular Imaging, 50 (13), 3970-3981. doi: 10.1007/s00259-023-06371-5

Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT)

Li, Minmin, Chan, David L., Tapia Rico, Gonzalo, Cehic, Gabrielle, Lawrence, Ben, Wyld, David, Pattison, David A., Kong, Grace, Hicks, Rodney, Michael, Michael, Kiberu, Andrew Ddembe, Lim, Jennifer, Clifton-Bligh, Roderick, Tsang, Venessa, Roach, Paul J., Leyden, John, Diakos, Connie I., Price, Timothy J. and Pavlakis, Nick (2023). Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT). Neuroendocrinology, 113 (3), 281-288. doi: 10.1159/000526848

Regional differences in the reduction in cerebral FDG uptake induced by the ketogenic diet

Bennett, O. A., Ramsay, S. C., Malacova, E., Bourgeat, P., Goodman, S. J., Dunn, C. J., Robinson, B. M., Lee, K. and Pattison, D. A. (2022). Regional differences in the reduction in cerebral FDG uptake induced by the ketogenic diet. European Journal of Hybrid Imaging, 6 (1) 29, 1-16. doi: 10.1186/s41824-022-00150-5

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

Buteau, James P, Martin, Andrew J, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen, Joshua, Anthony M, Francis, Roslyn J, Zhang, Alison Y, Scott, Andrew M, Lee, Sze-Ting, Azad, Arun A, McJannett, Margaret M, Stockler, Martin R, Williams, Scott G, Davis, Ian D, Hofman, Michael S, Akhurst, Tim, Alipour, Ramin, Banks, Patricia, Beaulieu, Alexis, Chua, Wei, Dhiantravan, Nattakorn, Ford, Kate, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J ... for the TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2022). PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. The Lancet Oncology, 23 (11), 1389-1397. doi: 10.1016/S1470-2045(22)00605-2

99mTc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis: Functional Imaging-Histopathologic Correlation

Wang, Ray, Better, Nathan, Sivaratnam, Dinesh, Westcott, James, Forehan, Simon, Christie, Michael, Pattison, David A. and Fourlanos, Spiros (2022). 99mTc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis: Functional Imaging-Histopathologic Correlation. Clinical Nuclear Medicine, 47 (9), E582-E584. doi: 10.1097/RLU.0000000000004332

All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others

Emmett, Louise, Pattison, David A. and Roberts, Matthew J. (2022). All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others. European urology oncology, 5 (3), 283-284. doi: 10.1016/j.euo.2022.04.002

Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)

Tariq, Arsalan, McGeorge, Stephen, Pearce, Adam, Rhee, Handoo, Wood, Simon, Kyle, Samuel, Marsh, Philip, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Westera, Jurjen, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John, Thomas, Paul, Pattison, David A. and Roberts, Matthew J. (2022). Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT). Urologic Oncology: Seminars and Original Investigations, 40 (6), 276.e1-276.e9. doi: 10.1016/j.urolonc.2022.03.007

The importance of training, accreditation, and guidelines for the practice of theranostics: the Australian perspective

Lee, Sze Ting, Emmett, Louise M., Pattison, David A., Hofman, Michael S., Bailey, Dale L., Latter, Melissa J., Francis, Roslyn J. and Scott, Andrew M. (2022). The importance of training, accreditation, and guidelines for the practice of theranostics: the Australian perspective. Journal of Nuclear Medicine, 63 (6), 819-822. doi: 10.2967/jnumed.122.263996

The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison

Tariq, Arsalan, Kwok, Michael, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Marsh, Phillip, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Westera, Jurjen, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John W., Thomas, Paul, Pattison, David A. and Roberts, Matthew J. (2022). The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. Urologic Oncology: Seminars and Original Investigations, 40 (2), 66.e1-66.e9. doi: 10.1016/j.urolonc.2021.11.006

[18F]GE-180 PET/CT assessment of enterocytic translocator protein (TSPO) over-expression: a pilot study in gastrointestinal GVHD

Scott, Ashleigh P., Thomas, Paul, Pattison, David A., Francis, Leo, Ridge, Paula, Tey, Siok-Keen and Kennedy, Glen A. (2022). [18F]GE-180 PET/CT assessment of enterocytic translocator protein (TSPO) over-expression: a pilot study in gastrointestinal GVHD. Bone Marrow Transplantation, 57 (3), 517-519. doi: 10.1038/s41409-022-01571-3

Lymph node classification in E-PSMA reporting guidelines for PSMA-PET

Arnfield, Evyn G., Roberts, Matthew J. and Pattison, David A. (2022). Lymph node classification in E-PSMA reporting guidelines for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 50 (1), 1-2. doi: 10.1007/s00259-022-05943-1

Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging

Chikatamarla, Venkata Avinash, Okano, Satomi, Jenvey, Peter, Ansaldo, Alexander, Roberts, Matthew J., Ramsay, Stuart C., Thomas, Paul A. and Pattison, David A. (2021). Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging. EJNMMI Research, 11 (1) 128, 128. doi: 10.1186/s13550-021-00869-5

The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study

Emmett, Louise, Buteau, James, Papa, Nathan, Moon, Daniel, Thompson, James, Roberts, Matthew J., Rasiah, Kris, Pattison, David A., Yaxley, John, Thomas, Paul, Hutton, Anthony C., Agrawal, Shikha, Amin, Amer, Blazevski, Alexandar, Chalasani, Venu, Ho, Bao, Nguyen, Andrew, Liu, Victor, Lee, Jonathan, Sheehan-Dare, Gemma, Kooner, Raji, Coughlin, Geoff, Chan, Lyn, Cusick, Thomas, Namdarian, Benjamin, Kapoor, Jada, Alghazo, Omar, Woo, Henry H., Lawrentschuk, Nathan ... Stricker, Phillip (2021). The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. European Urology, 80 (6), 682-689. doi: 10.1016/j.eururo.2021.08.002

Utility of 68Ga-DOTA-Exendin-4 PET/CT imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia

Kalff, Victor, Iravani, Amir, Ackhurst, Timothy, Pattison, David A., Eu, Peter, Hofman, Michael S. and Hicks, Rodney J. (2021). Utility of 68Ga-DOTA-Exendin-4 PET/CT imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia. Internal Medicine Journal, 51 (10) imj.15141, 1657-1664. doi: 10.1111/imj.15141

Dual-tracer positron-emission tomography using prostate-specific membrane antigen and fluorodeoxyglucose for staging of prostate cancer: a systematic review

McGeorge, Stephen, Kwok, Michael, Jiang, Andrew, Emmett, Louise, Pattison, David A., Thomas, Paul A., Yaxley, John W. and Roberts, Matthew J. (2021). Dual-tracer positron-emission tomography using prostate-specific membrane antigen and fluorodeoxyglucose for staging of prostate cancer: a systematic review. Advances in Urology, 2021 1544208, 1544208. doi: 10.1155/2021/1544208

PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics era

Ryder, Simon J., Love, Amanda J., Duncan, Emma L. and Pattison, David A. (2021). PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics era. Clinical Endocrinology, 95 (1), 13-28. doi: 10.1111/cen.14375

UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)

Dhiantravan, Nattakorn, Emmett, Louise, Joshua, Anthony M., Pattison, David A., Francis, Roslyn J., Williams, Scott, Sandhu, Shahneen, Davis, Ian D., Vela, Ian, Neha, Nitika, Bressel, Mathias, Murphy, Declan G., Hofman, Michael S. and Azad, Arun A. (2021). UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol). BJU International, 128 (3) bju.15384, 331-342. doi: 10.1111/bju.15384

124I-PET/CT-guided diagnosis and personalized treatment of metastatic papillary thyroid cancer to the pancreas

Wong, Bernadette Z Y, Dickie, Graeme, Garcia, Peter, Scott, Dominique and Pattison, David A. (2021). 124I-PET/CT-guided diagnosis and personalized treatment of metastatic papillary thyroid cancer to the pancreas. Clinical Nuclear Medicine, 46 (4), 337-339. doi: 10.1097/rlu.0000000000003499

Identification of Isolated Hepatic Sarcoidosis With 18F-FDG PET/CT and MRI

Arnfield, Evyn and Pattison, David A (2021). Identification of Isolated Hepatic Sarcoidosis With 18F-FDG PET/CT and MRI. Clinical Nuclear Medicine, Publish Ahead of Print (9), e448-e450. doi: 10.1097/rlu.0000000000003613

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A. ... TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 397 (10276), 797-804. doi: 10.1016/S0140-6736(21)00237-3

Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): the NETPET score as a prognostic biomarker

Chan, David L., Ulaner, Gary A., Pattison, David A., Wyld, David, Ladwa, Rahul, Kirchner, Julian, Li, Bob T, Lai, W Victoria, Pavlakis, Nick, Roach, Paul J and Bailey, Dale L (2021). Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): the NETPET score as a prognostic biomarker. Journal of Nuclear Medicine, 62 (9), 1278-1284. doi: 10.2967/jnumed.120.257659

68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer

Roberts, Matthew J., Morton, Andrew, Donato, Peter, Kyle, Samuel, Pattison, David A., Thomas, Paul, Coughlin, Geoff, Esler, Rachel, Dunglison, Nigel, Gardiner, Robert A., Doi, Suhail A., Emmett, Louise and Yaxley, John (2021). 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48 (2), 477-482. doi: 10.1007/s00259-020-04944-2

Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 48, 2, (477-482), 10.1007/s00259-020-04944-2)

Roberts, Matthew J., Morton, Andrew, Donato, Peter, Kyle, Samuel, Pattison, David A., Thomas, Paul, Coughlin, Geoff, Esler, Rachel, Dunglison, Nigel, Gardiner, Robert A., Doi, Suhail A., Emmett, Louise and Yaxley, John (2021). Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 48, 2, (477-482), 10.1007/s00259-020-04944-2). European Journal of Nuclear Medicine and Molecular Imaging, 48 (2), 655-656. doi: 10.1007/s00259-020-04983-9

Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation

Arnfield, Evyn G., Thomas, Paul A., Roberts, Matthew J., Pelecanos, Anita M., Ramsay, Stuart C., Lin, Charles Y., Latter, Melissa J., Garcia, Peter L. and Pattison, David A. (2021). Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. European Journal of Nuclear Medicine and Molecular Imaging, 48 (13), 4495-4507. doi: 10.1007/s00259-021-05456-3

Correction to: Prospective intra‑individual blinded comparison of [18F]PSMA‑1007 and [68 Ga]Ga‑PSMA‑11 PET/CT imaging in patients with confirmed prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 10.1007/s00259-021-05520-y)

Pattison, David A., Debowski, Maciej, Gulhane, Brook, Arnfield, Evyn G., Pelecanos, Anita M., Garcia, Peter L., Latter, Melissa J., Lin, Charles Y., Roberts, Matthew J., Ramsay, Stuart C. and Thomas, Paul A. (2021). Correction to: Prospective intra‑individual blinded comparison of [18F]PSMA‑1007 and [68 Ga]Ga‑PSMA‑11 PET/CT imaging in patients with confirmed prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 10.1007/s00259-021-05520-y). European Journal of Nuclear Medicine and Molecular Imaging, 49 (2), 789-789. doi: 10.1007/s00259-021-05548-0

Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer

Pattison, David A., Debowski, Maciej, Gulhane, Brook, Arnfield, Evyn G., Pelecanos, Anita M., Garcia, Peter L., Latter, Melissa J., Lin, Charles Y., Roberts, Matthew J., Ramsay, Stuart C. and Thomas, Paul A. (2021). Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 49 (2), 763-776. doi: 10.1007/s00259-021-05520-y

Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report

Dhanani, Jayesh, Pattison, David A., Burge, Matthew, Williams, Julian, Riedel, Bernhard, Hicks, Rodney J. and Reade, Michael C. (2020). Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. Journal of Critical Care, 60, 319-322. doi: 10.1016/j.jcrc.2020.08.011

The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT

Dudoignon, David, Pattison, David A., Legallois, Damien, Hicks, Rodney J. and Aide, Nicolas (2020). The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT. Cancer Imaging, 20 (1) 68, 1-12. doi: 10.1186/s40644-020-00344-9

68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer

Roberts, Matthew J., Morton, Andrew, Donato, Peter, Kyle, Samuel, Pattison, David A., Thomas, Paul, Coughlin, Geoff, Esler, Rachel, Dunglison, Nigel, Gardiner, Robert A., Doi, Suhail A., Emmett, Louise and Yaxley, John (2020). 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48 (2), 655-656. doi: 10.1007/s00259-020-04944-2

Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer

Violet, John, Sandhu, Shahneen, Iravani, Amir, Ferdinandus, Justin, Sue-Ping Thang, , Kong, Grace, Kumar, Aravind Ravi, Akhurst, Tim, Pattison, David, Beaulieu, Alexis, Mooi, Jennifer, Tran, Ben, Guo, Christina, Kalff, Victor, Murphy, Declan G., Jackson, Price, Eu, Peter, Scalzo, Mark, Williams, Scott G., Hicks, Rod J., Hofman, Michael S. and Tran, Ben (2020). Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine, 61 (6), 857-865. doi: 10.2967/jnumed.119.236414

Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer

Violet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S. P., Kong, G., Kumar, A. Ravi, Akhurst, T., Pattison, D. A., Beaulieu, A., Mooi, J., Guo, C., Kalff, V., Murphy, D. G., Jackson, P., Eu, P., Scalzo, M., Williams, S., Hicks, R. J. and Hofman, M. S. (2020). Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer. Journal of Urology, 203 (5). doi: 10.1097/JU.0000000000000779.01

Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol

Iravani, Amir, Solomon, Benjamin, Pattison, David A., Jackson, Price, Ravi Kumar, Aravind, Kong, Grace, Hofman, Michael S., Akhurst, Tim and Hicks, Rodney J. (2019). Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol. Thyroid, 29 (11), 1634-1645. doi: 10.1089/thy.2019.0143

Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT

Pattison, David A., MacFarlane, Lisa L., Callahan, Jason, Kane, Emma L., Akhurst, Timothy and Hicks, Rodney J. (2019). Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. EJNMMI Research, 9 (1) 15, 15. doi: 10.1186/s13550-019-0480-2

64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy

Hicks, Rodney J., Jackson, Price, Kong, Grace, Ware, Robert E., Hofman, Michael S., Pattison, David A., Akhurst, Timothy A., Drummond, Elizabeth, Roselt, Peter, Callahan, Jason, Price, Roger, Jeffery, Charmaine M., Hong, Emily, Noonan, Wayne, Herschtal, Alan, Hicks, Lauren J., Hedt, Amos, Harris, Matthew, Paterson, Brett M. and Donnelly, Paul S. (2018). 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. Journal of Nuclear Medicine, 60 (6), 777-785. doi: 10.2967/jnumed.118.217745

Lymphangitic carcinomatosis from prostate cancer identified with gallium-68 prostate-specific membrane antigen positron emission tomography imaging

Tang, Victor, Campbell, Patrina and Pattison, David A. (2018). Lymphangitic carcinomatosis from prostate cancer identified with gallium-68 prostate-specific membrane antigen positron emission tomography imaging. Urology, 114, e1-e2. doi: 10.1016/j.urology.2017.12.010

Diagnostic challenges in a patient with an occult insulinoma:68 Ga-DOTA-exendin-4 PET/CT and68Ga-DOTATATE PET/CT

Bongetti, Elisa, Lee, Melissa H., Pattison, David A., Hicks, Rodney J., Norris, Richard, Sachithanandan, Nirupa and MacIsaac, Richard J. (2018). Diagnostic challenges in a patient with an occult insulinoma:68 Ga-DOTA-exendin-4 PET/CT and68Ga-DOTATATE PET/CT. Clinical Case Reports, 6 (4), 719-722. doi: 10.1002/ccr3.1448

Tumor cystic necrosis following peptide receptor radionuclide therapy in neuroendocrine tumors

Ladwa, Rahul, Wen Hong, Hooi, Wyld, David, Pattison, David A. and Burge, Matthew (2018). Tumor cystic necrosis following peptide receptor radionuclide therapy in neuroendocrine tumors. Clinical Nuclear Medicine, 43 (3), 186-187. doi: 10.1097/RLU.0000000000001970

Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging

Mossman, Anna K., Pattison, David A., Hicks, Rodney J., Hamblin, Peter S. and Yates, Christopher J. (2018). Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. Internal Medicine Journal, 48 (1), 97-98. doi: 10.1111/imj.13664

18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation

Pattison, David A., Bozin, Michael, Gorelik, Alexandra, Hofman, Michael S., Hicks, Rodney J. and Skandarajah, Anita (2017). 18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. Journal of Nuclear Medicine, 59 (5), 749-755. doi: 10.2967/jnumed.117.198085

Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma

Kong, Grace, Grozinsky-Glasberg, Simona, Hofman, Michael S., Callahan, Jason, Meirovitz, Amichay, Maimon, Ofra, Pattison, David A., Gross, David J. and Hicks, Rodney J. (2017). Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. The Journal of Clinical Endocrinology & Metabolism, 102 (9), 3278-3287. doi: 10.1210/jc.2017-00816

Molecular imaging in the investigation of hypoglycaemic syndromes and their management

Pattison, David A. and Hicks, Rodney J. (2017). Molecular imaging in the investigation of hypoglycaemic syndromes and their management. Endocrine-Related Cancer, 24 (6), R203-R221. doi: 10.1530/erc-17-0005

High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours

Kong, Grace, Callahan, Jason, Hofman, Michael S., Pattison, David A., Akhurst, Tim, Michael, Michael, Eu, Peter and Hicks, Rodney J. (2016). High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 44 (3), 476-489. doi: 10.1007/s00259-016-3527-x

THYROPET Study: Is It Biology or Technology That Is the Issue?

Pattison, David A. and Hicks, Rodney J. (2016). THYROPET Study: Is It Biology or Technology That Is the Issue?. Journal of Nuclear Medicine, 58 (2), 354-354. doi: 10.2967/jnumed.116.181420

68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity

Chang, Chian A., Pattison, David A., Tothill, Richard W., Kong, Grace, Akhurst, Tim J., Hicks, Rodney J. and Hofman, Michael S. (2016). 68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging, 16 (1) 22. doi: 10.1186/s40644-016-0084-2

Intense focal pituitary FDG uptake due to intravascular large B-cell lymphoma in pyrexia of unknown origin : FDG-Avid Pituitary & Intravascular Lymphoma

Pattison, David A., Hofman, Michael S., Bazargan, Ali, Colman, Peter and Hicks, Rodney J. (2016). Intense focal pituitary FDG uptake due to intravascular large B-cell lymphoma in pyrexia of unknown origin : FDG-Avid Pituitary & Intravascular Lymphoma. American Journal of Hematology, 91 (11), 1167-1168. doi: 10.1002/ajh.24469

A New Theranostic Paradigm for Advanced Thyroid Cancer

Pattison, David A., Solomon, Benjamin and Hicks, Rodney J. (2016). A New Theranostic Paradigm for Advanced Thyroid Cancer. Journal of Nuclear Medicine, 57 (10), 1493-1494. doi: 10.2967/jnumed.116.173534

Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies

Pattison, David A. and Hofman, Michael S. (2015). Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies. PET Clinics, 10 (4), 461-476. doi: 10.1016/j.cpet.2015.05.005

Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis

Pattison, David A., Westcott, James, Lichtenstein, Meir, Toh, H.B., Gunawardana, Dishan, Better, Nathan, Forehan, Simon and Sivaratnam, Dinesh (2015). Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nuclear Medicine Communications, 36 (4), 356-362. doi: 10.1097/mnm.0000000000000260

Enhanced White Adipose Tissue Metabolism in Iatrogenic Cushing's Syndrome With FDG PET/CT

Pattison, David A., Hofman, Michael S., Lau, Eddie, Ware, Rob and Hicks, Rodney J. (2014). Enhanced White Adipose Tissue Metabolism in Iatrogenic Cushing's Syndrome With FDG PET/CT. The Journal of Clinical Endocrinology & Metabolism, 99 (9), 3041-3042. doi: 10.1210/jc.2013-4090

Intracoronary 99m Tc-Sestamibi Single Photon Emission Computed Tomography/Computed Tomography for Preoperative Evaluation of At-Risk Myocardium

Pattison, David, Westcott, James, Ajani, Andrew, Antippa, Phillip, Joshi, Subodh, Lui, Elaine, Langenberg, Francesca and Better, Nathan (2013). Intracoronary 99m Tc-Sestamibi Single Photon Emission Computed Tomography/Computed Tomography for Preoperative Evaluation of At-Risk Myocardium. Circulation, 128 (5), 567-570. doi: 10.1161/circulationaha.113.001417

Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines

Cheung, A. S., Pattison, D., Bretherton, I., Hoermann, R., Lim Joon, D., Ho, E., Jenkins, T., Hamilton, E. J., Bate, K., Chan, I., Zajac, J. D. and Grossmann, M. (2013). Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. Andrology, 1 (4), 583-589. doi: 10.1111/j.2047-2927.2013.00093.x

An endocrine cause of acute post-partum hypertension

Bretherton, Ingrid, Pattison, David, Pattison, Sarah and Varadarajan, Suresh (2013). An endocrine cause of acute post-partum hypertension. Obstetric Medicine, 6 (1), 30-32. doi: 10.1258/om.2012.120012

Amiodarone-Induced Destructive Thyroiditis Associated with Coronary Artery Vasospasm and Recurrent Ventricular Fibrillation

Brooks, Matthew J., Pattison, David A., Teo, Eliza P., Price, Sarah and Gurvitch, Ronen (2012). Amiodarone-Induced Destructive Thyroiditis Associated with Coronary Artery Vasospasm and Recurrent Ventricular Fibrillation. European Thyroid Journal. doi: 10.1159/000345528

Exercise-associated hyponatraemia on the Kokoda Track

Pattison, David A., Walters, Tomos E. and Seal, Eric (2011). Exercise-associated hyponatraemia on the Kokoda Track. Medical Journal of Australia, 194 (5), 247-248. doi: 10.5694/j.1326-5377.2011.tb02956.x

Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis

Soule, Steven, Florkowski, Chris, Potter, Howard, Pattison, David, Swan, Martin, Hunt, Penny and George, Peter (2008). Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 45 (5), 520-523. doi: 10.1258/acb.2007.007211

Strongyloidiasis in personnel of the Regional Assistance Mission to Solomon Islands (RAMSI)

Pattison, David A. and Speare, Richard (2008). Strongyloidiasis in personnel of the Regional Assistance Mission to Solomon Islands (RAMSI). Medical Journal of Australia, 189 (4), 203-206. doi: 10.5694/j.1326-5377.2008.tb01982.x

Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial

Roberts, Matthew, Roberts, Natasha, Harley, Simon, Cullen, Karla, Pelecanos, Anita, Vela, Ian, Yaxley, John, Kuchel, Anna, Dhiantravan, Nattakorn, Thomas, Paul and Pattison, David (2023). Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley.

Evolution: Phase II study of radionuclide ¹⁷⁷Lu-PSMA-617 therapy versus ¹⁷⁷Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)

Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Lee, Sze Ting, Weickhardt, Andrew James, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps271

Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: <SUP>177</SUP>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final results

Pavlakis, Nick, Ransom, David Turner, Wyld, David, Sjoquist, Katrin Marie, Wilson, Kate, Gebski, Val, Murray, James, Kiberu, Andrew Ddembe, Burge, Matthew E., Macdonald, William, Roach, Paul, Pattison, David A., Butler, Patrick, Price, Timothy Jay, Michael, Michael, Lawrence, Benjamin James, Bailey, Dale L., Leyden, Simone, Zalcberg, John Raymond and Turner, Harvey (2022). Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)-Final results. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

TheraP: <SUP>177</SUP>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603)

Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2022). TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: a real-world retrospective review of efficacy and safety from an Australian tertiary cancer Center

Nalder, Mark, Ladwa, Rahul, Raina, Anant, Burge, Matthew E., Love, Amanda, Pattison, David A., Ramsay, Stuart and Wyld, David (2021). 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: a real-world retrospective review of efficacy and safety from an Australian tertiary cancer Center. 2021 ASCO Annual Meeting I, Virtual, 4-8 June 2021. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2021.39.15_suppl.e16198

Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study]

Sandhu, Shahneen, Tothill, Richard, Scolyer, Richard, Guminski, Alexander, Becker, Juergen, Poulsen, Michael, Atkinson, Victoria, Neeson, Paul, Shackleton, Mark, Pattison, David, Williams, Narelle and Paton, Elizabeth (2019). Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study]. COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, Adelaide, SA, Australia, 12–14 November 2019. Hoboken, NJ, United States: Wiley.

A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68GA-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer

Debowski, M., Gulhane, B., Ramsay, S. C., Thomas, P. A., Garcia, P., Latter, M., Tapper, S. and Pattison, D. A. (2019). A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68GA-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. Australian and New Zealand Society of Nuclear Medicine (ANZSNM) 49th ASM, Adelaide, SA, Australia, 26–28 April 2019. Hoboken, NJ, United States: Wiley.

Targeted Molecular Imaging of Translocator Protein (TSPO) Using (18F)GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD)

Scott, Ashleigh P., Tey, Siok-Keen, Thomas, Paul, Pattison, David and Kennedy, Glen A. (2018). Targeted Molecular Imaging of Translocator Protein (TSPO) Using (18F)GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD). 60th Annual Meeting of the American Society of Hematology (ASH), San Diego, CA United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-114114

(18)FDG PET/CT CARDIAC SARCOID IMAGING: MONITORING KETONE LEVELS TO AVOID INADEQUATE SUPPRESSION OF PHYSIOLOGIC MYOCARDIAL UPTAKE

Robinson, B., Pattison, D. and Lee, K. (2018). (18)FDG PET/CT CARDIAC SARCOID IMAGING: MONITORING KETONE LEVELS TO AVOID INADEQUATE SUPPRESSION OF PHYSIOLOGIC MYOCARDIAL UPTAKE. HOBOKEN: WILEY.

Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET)

Ladwa, R., Pattison, D., Smith, J., Goodman, S., Burge, M., Rose, S., Dowson, N. and Wyld, D. (2018). Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET). 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG.

Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumors

Ladwa, R., Pattison, D., Smith, J., Goodman, S., Burg, M., Rose, S., Dowson, N. and Wyld, D. (2018). Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumors. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG.

Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumor

Ladwa, R., Pattison, D., Smith, J., Goodman, S., Burge, M., Rose, S., Dowson, N. and Wyld, D. (2018). Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumor. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG.

Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECT

Goodman, Steven , Patford, Shaun , Ladwa, Rahul , Smith, Jye , Wyld, David and Pattison, David A. (2018). Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECT. 12th Congress of the World Federation of Nuclear Medicine and Biology., Melbourne Australia, 20-24 April 2018.

177Lu-DOTA-OCTREOTATE PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN PATIENTS WITH FUNCTIONAL AND METASTATIC PHAEOCHROMOCYTOMA (PCC) OR PARAGANGLIOMA (PGL)

Kong, G., Grozinsky-Glasberg, S., Callahan, J., Hofman, M. S., Meirovitz, A., Maimon, O., Pattison, D. A., Gross, D. J. and Hicks, R. J. (2017). 177Lu-DOTA-OCTREOTATE PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN PATIENTS WITH FUNCTIONAL AND METASTATIC PHAEOCHROMOCYTOMA (PCC) OR PARAGANGLIOMA (PGL). HOBOKEN: WILEY.

USING A FORMULA BASED ON BMI AND BSL FOR ADMINISTRATION OF ACTRAPID FOR FDG-PET SCANS WHERE THE PATIENT'S BSL IS ELEVATED ON ARRIVAL

MacFarlane, L. and Pattison, D. (2017). USING A FORMULA BASED ON BMI AND BSL FOR ADMINISTRATION OF ACTRAPID FOR FDG-PET SCANS WHERE THE PATIENT'S BSL IS ELEVATED ON ARRIVAL. HOBOKEN: WILEY.

Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)

Kong, G., Grozinsky-Glasberg, S., Callahan, J., Hofman, M., Meirovitz, A., Maimon, O., Pattison, D., Gross, D. and Hicks, R. (2017). Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL). 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona Spain, Mar 08-10, 2017. BASEL: KARGER.

The management of refractory catecholamine associated symptoms in malignant phaeochromocytoma

Mossman, Anna, Pattison, David, Inchley, Fiona and Hamblin, P. Shane (2017). The management of refractory catecholamine associated symptoms in malignant phaeochromocytoma. HOBOKEN: WILEY-BLACKWELL.

HIGH EFFICACY FROM A PERSONALISED APPROACH USING Y-90-DOTA-OCTREOTATE SEQUENCED WITH (LU)-L-177-DOTA-OCTREOTATE INDUCTION PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT) FOR BULKY NEUROENDOCRINE TUMOURS

Kong, G., Callahan, J., Hofman, M., Pattison, D., Akhurst, T., Michael, M., Eu, P. and Hicks, R. (2016). HIGH EFFICACY FROM A PERSONALISED APPROACH USING Y-90-DOTA-OCTREOTATE SEQUENCED WITH (LU)-L-177-DOTA-OCTREOTATE INDUCTION PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT) FOR BULKY NEUROENDOCRINE TUMOURS. HOBOKEN: WILEY-BLACKWELL.

PRELIMINARY RESULTS OF (68)GA EXENDIN-4 PET/CT IMAGING OF NEUROENDOCRINE TUMOURS (NETS)

Pattison, D., Kong, G., Messazos, B., Hamblin, P., Fourlanos, S., Lee, M., Michael, M., Hong, E., Eu, P. and Hicks, R. (2016). PRELIMINARY RESULTS OF (68)GA EXENDIN-4 PET/CT IMAGING OF NEUROENDOCRINE TUMOURS (NETS). HOBOKEN: WILEY-BLACKWELL.

Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)

Kong, G., Callahan, J., Hofman, M., Pattison, D., Akhurst, T., Michael, M., Eu, P. and Hicks, R. (2016). Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT). 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona Spain, Mar 09-11, 2016. BASEL: KARGER.

MANAGEMENT OF HYPERTENSIVE CRISIS IN PARAGANGLIOMA-A CASE REPORT

Jackson, Cheryl, Lingaratnam, Senthil, Michael, Michael and Pattison, David (2015). MANAGEMENT OF HYPERTENSIVE CRISIS IN PARAGANGLIOMA-A CASE REPORT. HOBOKEN: WILEY-BLACKWELL.

GA-68 DOTA-OCTREOTATE (GATATE) AND F-18 FLUORODEOXYGLUCOSE (FDG) PET/CT IN THE ASSESSMENT OF PARAGANGLIOMAS AND PHEOCHROMOCYTOMAS

Chang, C. A., Hofman, M., Thompson, M., Pattison, D. and Hicks, R. (2015). GA-68 DOTA-OCTREOTATE (GATATE) AND F-18 FLUORODEOXYGLUCOSE (FDG) PET/CT IN THE ASSESSMENT OF PARAGANGLIOMAS AND PHEOCHROMOCYTOMAS. HOBOKEN: WILEY-BLACKWELL.

IMPROVED SURVIVAL OF POOR PROGNOSIS FDG-AVID NEUROENDOCRINE TUMOURS WITH LU-177 OCTREOTATE PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT)

Hofman, M. S., Kashyap, R., Kong, G., Akhurst, T., Pattison, D., Eu, P. and Hicks, R. J. (2015). IMPROVED SURVIVAL OF POOR PROGNOSIS FDG-AVID NEUROENDOCRINE TUMOURS WITH LU-177 OCTREOTATE PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT). HOBOKEN: WILEY-BLACKWELL.

STONES, GROANS AND BONES

Crowther, M. and Pattison, D. (2014). STONES, GROANS AND BONES. HOBOKEN: WILEY-BLACKWELL.

APPEARANCE OF 99MTC-SESTAMIBI THYROID SCINTIGRAPHY WITH CALCULATION OF THYROID-TO-BACKGROUND RATIO IN PATIENTS WITH GRAVES' DISEASE, TOXIC MULTINODULAR GOITRE AND HYPOTHYROIDISM

Pattison, David, Westcott, James, Sivaratnam, Dinesh and Lichtenstein, Meir (2013). APPEARANCE OF 99MTC-SESTAMIBI THYROID SCINTIGRAPHY WITH CALCULATION OF THYROID-TO-BACKGROUND RATIO IN PATIENTS WITH GRAVES' DISEASE, TOXIC MULTINODULAR GOITRE AND HYPOTHYROIDISM. HOBOKEN: WILEY-BLACKWELL.

ESTIMATION OF QUANTITATIVE THYROID-TO-BACKGROUND RATIO FOR Tc-99m-SESTAMIBI THYROID SCINTIGRAPHY IN PATIENTS WITH NORMAL THYROID FUNCTION

Pattison, David, Westcott, James, Toh, Hock Boon, Lichtenstein, Meir and Sivaratnam, Dinesh (2013). ESTIMATION OF QUANTITATIVE THYROID-TO-BACKGROUND RATIO FOR Tc-99m-SESTAMIBI THYROID SCINTIGRAPHY IN PATIENTS WITH NORMAL THYROID FUNCTION. HOBOKEN: WILEY-BLACKWELL.

PRE-OPERATIVE EVALUATION OF 'AT RISK' MYOCARDIUM WITH INTRACORONARY 99mTc-SESTAMIBI SPECT/CT

Westcott, James, Pattison, David, Ajani, Andrew, Antippa, Phillip, Heinze, Stefan, Joshi, Subodh, Lui, Elaine, Langenberg, Francesca and Better, Nathan (2013). PRE-OPERATIVE EVALUATION OF 'AT RISK' MYOCARDIUM WITH INTRACORONARY 99mTc-SESTAMIBI SPECT/CT. HOBOKEN: WILEY-BLACKWELL.

QUANTITATIVE ASSESSMENT OF THYROID-TO-BACKGROUND RATIO IMPROVES THE INTER-OBSERVER RELIABILITY OF 99 m-Tc SESTAMIBI THYROID SCINTIGRAPHY FOR INVESTIGATION OF AMIODARONE-INDUCED THYROTOXICOSIS

Pattison, David, Westcott, James, Lichtenstein, Meir, Toh, Hock Boon, Gunawardana, Dishan, Better, Nathan, Forehan, Simon and Sivaratnam, Dinesh (2013). QUANTITATIVE ASSESSMENT OF THYROID-TO-BACKGROUND RATIO IMPROVES THE INTER-OBSERVER RELIABILITY OF 99 m-Tc SESTAMIBI THYROID SCINTIGRAPHY FOR INVESTIGATION OF AMIODARONE-INDUCED THYROTOXICOSIS. HOBOKEN: WILEY-BLACKWELL.